Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity [Yahoo! Finance]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Yahoo! Finance
On February 17, Myles Minter from William Blair upgraded his rating on Neumora Therapeutics Inc. (NASDAQ:NMRA) from Market Perform to Outperform. The analyst also shared a net present value figure of $7.62 per share for the stock's valuation. Minter anticipated a rising success probability of 35% for the company's NMRA-511, which is utilized in Alzheimer's disease agitation. This came after data revealed by Neumora Therapeutics Inc. (NASDAQ:NMRA) on the Phase Ib study. The analyst noted that the study revealed some meaningful cuts in the Cohen-Mansfield Agitation Inventory endpoint. He maintains his views on Alzheimer's disease agitation, which he sees as a massive opportunity within the market. Moreover, based on some conservative underlying assumptions, Minter has projected peak U.S. sales figures of around $1.8 billion for NMRA-511. Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity Copyright: dolgachov / 123RF Stock Photo Neumora Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026GlobeNewswire
- Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.MarketBeat
NMRA
Earnings
- 11/6/25 - Miss
NMRA
Sec Filings
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- NMRA's page on the SEC website